Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Tests | 9 | 2024 | 24 | 2.950 |
Why?
|
| Disseminated Intravascular Coagulation | 4 | 2022 | 14 | 2.750 |
Why?
|
| Automation, Laboratory | 3 | 2020 | 13 | 1.930 |
Why?
|
| Blood Coagulation | 6 | 2022 | 29 | 1.700 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 3 | 2024 | 8 | 1.690 |
Why?
|
| Anticoagulants | 5 | 2020 | 57 | 1.580 |
Why?
|
| Hemostatics | 2 | 2022 | 17 | 1.520 |
Why?
|
| Humans | 55 | 2024 | 14537 | 1.490 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2019 | 56 | 1.370 |
Why?
|
| Enoxaparin | 2 | 2020 | 14 | 1.360 |
Why?
|
| HIV Infections | 10 | 2024 | 5097 | 1.280 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 43 | 1.260 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 91 | 1.250 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 5 | 2024 | 19 | 1.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 237 | 1.170 |
Why?
|
| von Willebrand Factor | 6 | 2024 | 21 | 1.120 |
Why?
|
| von Willebrand Diseases | 3 | 2022 | 8 | 1.030 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 20 | 0.930 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 217 | 0.910 |
Why?
|
| Hematology | 1 | 2024 | 4 | 0.910 |
Why?
|
| Factor VIII | 1 | 2024 | 54 | 0.900 |
Why?
|
| Hemoglobins | 2 | 2022 | 40 | 0.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 77 | 0.890 |
Why?
|
| Quality Control | 3 | 2020 | 27 | 0.870 |
Why?
|
| Hemophilia A | 1 | 2024 | 106 | 0.830 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 5 | 0.820 |
Why?
|
| Female | 25 | 2024 | 9103 | 0.810 |
Why?
|
| Virus Diseases | 2 | 2023 | 55 | 0.810 |
Why?
|
| Venous Thromboembolism | 3 | 2019 | 27 | 0.810 |
Why?
|
| Male | 25 | 2024 | 6754 | 0.790 |
Why?
|
| International Normalized Ratio | 3 | 2018 | 17 | 0.790 |
Why?
|
| Tertiary Care Centers | 2 | 2022 | 80 | 0.760 |
Why?
|
| Platelet Activation | 1 | 2021 | 17 | 0.760 |
Why?
|
| South Africa | 25 | 2022 | 7596 | 0.750 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 563 | 0.730 |
Why?
|
| Freezing | 1 | 2020 | 6 | 0.730 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 3 | 0.730 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.720 |
Why?
|
| Anemia | 1 | 2020 | 41 | 0.700 |
Why?
|
| Plasma Exchange | 1 | 2019 | 2 | 0.660 |
Why?
|
| Hemostasis | 1 | 2019 | 15 | 0.650 |
Why?
|
| Immunoturbidimetry | 1 | 2019 | 3 | 0.650 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 14 | 0.640 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 4 | 0.640 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 44 | 0.620 |
Why?
|
| Middle Aged | 18 | 2024 | 3601 | 0.620 |
Why?
|
| Drug Monitoring | 2 | 2018 | 55 | 0.610 |
Why?
|
| ADAMTS13 Protein | 3 | 2024 | 8 | 0.610 |
Why?
|
| Warfarin | 1 | 2018 | 19 | 0.600 |
Why?
|
| Retrospective Studies | 4 | 2022 | 799 | 0.600 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 30 | 0.590 |
Why?
|
| Thrombosis | 5 | 2024 | 47 | 0.580 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 266 | 0.580 |
Why?
|
| Specimen Handling | 1 | 2018 | 105 | 0.570 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 551 | 0.540 |
Why?
|
| Adult | 20 | 2024 | 5913 | 0.520 |
Why?
|
| Risk Factors | 7 | 2024 | 1475 | 0.480 |
Why?
|
| Biomarkers | 4 | 2023 | 327 | 0.440 |
Why?
|
| Blood Platelets | 2 | 2022 | 30 | 0.380 |
Why?
|
| Venous Thrombosis | 2 | 2010 | 14 | 0.380 |
Why?
|
| Laboratories | 2 | 2024 | 47 | 0.380 |
Why?
|
| Fibrinogen | 2 | 2022 | 10 | 0.350 |
Why?
|
| Prothrombin Time | 2 | 2022 | 15 | 0.350 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.330 |
Why?
|
| Pandemics | 2 | 2021 | 296 | 0.310 |
Why?
|
| Prevalence | 5 | 2019 | 1192 | 0.290 |
Why?
|
| Asthma | 4 | 1995 | 33 | 0.290 |
Why?
|
| Aged | 10 | 2018 | 1740 | 0.270 |
Why?
|
| Hemorrhage | 2 | 2018 | 72 | 0.250 |
Why?
|
| Chromogenic Compounds | 1 | 2024 | 1 | 0.240 |
Why?
|
| Blood Cell Count | 2 | 2024 | 15 | 0.240 |
Why?
|
| Cattle | 1 | 2024 | 28 | 0.240 |
Why?
|
| Altitude | 1 | 2024 | 9 | 0.230 |
Why?
|
| Autoantibodies | 1 | 2024 | 49 | 0.230 |
Why?
|
| Japan | 1 | 2024 | 7 | 0.230 |
Why?
|
| Leukocyte Count | 1 | 2024 | 24 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 44 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2023 | 51 | 0.210 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 4 | 0.210 |
Why?
|
| Hemolysis | 1 | 2022 | 7 | 0.210 |
Why?
|
| Spirometry | 3 | 1998 | 12 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 468 | 0.210 |
Why?
|
| Acute-Phase Proteins | 1 | 2022 | 14 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 125 | 0.200 |
Why?
|
| Time Factors | 4 | 2018 | 507 | 0.200 |
Why?
|
| Cytokines | 1 | 2023 | 107 | 0.200 |
Why?
|
| Mean Platelet Volume | 1 | 2021 | 3 | 0.190 |
Why?
|
| Platelet Count | 1 | 2021 | 14 | 0.190 |
Why?
|
| Animals | 1 | 2024 | 1081 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 11 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.190 |
Why?
|
| Cryopreservation | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hematologic Tests | 1 | 2020 | 11 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 253 | 0.180 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2020 | 1 | 0.180 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2020 | 1 | 0.180 |
Why?
|
| Glutaryl-CoA Dehydrogenase | 1 | 2020 | 1 | 0.180 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2020 | 2 | 0.180 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 47 | 0.180 |
Why?
|
| Prothrombin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 7 | 0.170 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Clinical Laboratory Services | 1 | 2019 | 4 | 0.170 |
Why?
|
| Research | 2 | 1998 | 65 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 14 | 0.160 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 385 | 0.160 |
Why?
|
| Linear Models | 1 | 2019 | 83 | 0.160 |
Why?
|
| Smoking | 2 | 1996 | 100 | 0.160 |
Why?
|
| Antithrombins | 1 | 2018 | 2 | 0.150 |
Why?
|
| Centrifugation | 1 | 2018 | 2 | 0.150 |
Why?
|
| Partial Thromboplastin Time | 1 | 2018 | 13 | 0.150 |
Why?
|
| Postpartum Period | 1 | 2019 | 85 | 0.150 |
Why?
|
| Temperature | 1 | 2018 | 56 | 0.150 |
Why?
|
| Mutation | 1 | 2019 | 306 | 0.150 |
Why?
|
| Virulence Factors | 1 | 2018 | 18 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.150 |
Why?
|
| Thyroid Diseases | 1 | 1997 | 1 | 0.150 |
Why?
|
| Geriatrics | 1 | 1997 | 2 | 0.150 |
Why?
|
| Thyrotropin | 1 | 1997 | 5 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1997 | 6 | 0.140 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 75 | 0.140 |
Why?
|
| Comorbidity | 1 | 2018 | 188 | 0.140 |
Why?
|
| Mental Status Schedule | 1 | 1996 | 1 | 0.130 |
Why?
|
| Pregnancy | 2 | 2019 | 1862 | 0.130 |
Why?
|
| Students, Medical | 1 | 1996 | 14 | 0.130 |
Why?
|
| Thrombelastography | 2 | 2024 | 6 | 0.130 |
Why?
|
| Dementia | 1 | 1996 | 22 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 1996 | 30 | 0.130 |
Why?
|
| Infant | 2 | 2020 | 2244 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2010 | 14 | 0.110 |
Why?
|
| Vena Cava Filters | 1 | 2013 | 4 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1748 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 9 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 20 | 0.110 |
Why?
|
| Respiratory Function Tests | 2 | 1990 | 10 | 0.100 |
Why?
|
| Adolescent | 3 | 2018 | 2985 | 0.100 |
Why?
|
| Child | 1 | 2018 | 2242 | 0.100 |
Why?
|
| Young Adult | 1 | 2018 | 2498 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2010 | 10 | 0.090 |
Why?
|
| Atropine Derivatives | 1 | 1990 | 1 | 0.090 |
Why?
|
| Ipratropium | 1 | 1990 | 2 | 0.090 |
Why?
|
| Fenoterol | 1 | 1990 | 3 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2009 | 6 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2010 | 480 | 0.080 |
Why?
|
| Reference Values | 4 | 2007 | 64 | 0.080 |
Why?
|
| Workers' Compensation | 1 | 1988 | 5 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 1988 | 40 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 2 | 1987 | 9 | 0.070 |
Why?
|
| Platelet Aggregation | 1 | 2007 | 12 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 12 | 0.070 |
Why?
|
| Aspirin | 1 | 2007 | 15 | 0.070 |
Why?
|
| HIV Seroprevalence | 1 | 2007 | 15 | 0.070 |
Why?
|
| Vital Capacity | 3 | 1996 | 6 | 0.060 |
Why?
|
| Forced Expiratory Volume | 3 | 1996 | 9 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2024 | 32 | 0.060 |
Why?
|
| Air Travel | 1 | 2024 | 4 | 0.060 |
Why?
|
| Oximetry | 1 | 2024 | 6 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 18 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 1996 | 411 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 1995 | 39 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 231 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 279 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 1324 | 0.040 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Sudden Infant Death | 1 | 2020 | 2 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 2020 | 12 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 11 | 0.040 |
Why?
|
| DNA | 1 | 2020 | 73 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1996 | 133 | 0.040 |
Why?
|
| Anthropometry | 2 | 1996 | 102 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 442 | 0.040 |
Why?
|
| Flaviviridae | 1 | 1997 | 1 | 0.040 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1997 | 3 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 1997 | 1 | 0.040 |
Why?
|
| Lung | 2 | 1996 | 70 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 370 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2010 | 1160 | 0.030 |
Why?
|
| Plants, Toxic | 1 | 1996 | 2 | 0.030 |
Why?
|
| Tobacco | 1 | 1996 | 14 | 0.030 |
Why?
|
| Psychometrics | 1 | 1996 | 22 | 0.030 |
Why?
|
| Rural Population | 2 | 1997 | 654 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 80 | 0.030 |
Why?
|
| Mass Screening | 2 | 1997 | 245 | 0.030 |
Why?
|
| Educational Status | 1 | 1996 | 68 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1996 | 36 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1995 | 6 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1995 | 10 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 1479 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1974 | 6 | 0.030 |
Why?
|
| Acute Disease | 2 | 1995 | 105 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1996 | 240 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 3 | 0.030 |
Why?
|
| beta-Alanine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Thiophenes | 1 | 2013 | 4 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2013 | 6 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 5 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2013 | 11 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2013 | 13 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1997 | 1422 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 74 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2013 | 225 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1992 | 107 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 252 | 0.020 |
Why?
|
| Protein S | 1 | 2010 | 3 | 0.020 |
Why?
|
| Protein C | 1 | 2010 | 4 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 45 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 77 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1990 | 112 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1990 | 2 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1990 | 2 | 0.020 |
Why?
|
| Random Allocation | 1 | 1990 | 23 | 0.020 |
Why?
|
| Medicine in the Arts | 1 | 2009 | 3 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1990 | 272 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 435 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 1987 | 324 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 656 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 64 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 25 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 889 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1987 | 8 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1987 | 29 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 819 | 0.020 |
Why?
|
| Prednisone | 1 | 1984 | 17 | 0.010 |
Why?
|
| Prognosis | 1 | 1984 | 199 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1987 | 63 | 0.010 |
Why?
|
| Aminophylline | 1 | 1995 | 1 | 0.010 |
Why?
|
| Albuterol | 1 | 1995 | 6 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1995 | 7 | 0.010 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 1974 | 1 | 0.010 |
Why?
|
| Pericardium | 1 | 1974 | 2 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1974 | 4 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1997 | 967 | 0.010 |
Why?
|
| Urban Population | 1 | 1996 | 257 | 0.010 |
Why?
|
| Bacteriuria | 1 | 1973 | 1 | 0.010 |
Why?
|
| Tuberculosis, Urogenital | 1 | 1973 | 1 | 0.010 |
Why?
|
| Pneumonia | 1 | 1974 | 131 | 0.010 |
Why?
|
| Sulfonic Acids | 1 | 1971 | 3 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 1971 | 9 | 0.010 |
Why?
|
| Nocardia Infections | 1 | 1987 | 1 | 0.000 |
Why?
|
| Dyspnea | 1 | 1987 | 10 | 0.000 |
Why?
|
| Hypertension | 1 | 1971 | 419 | 0.000 |
Why?
|
| Furans | 1 | 1971 | 4 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1971 | 6 | 0.000 |
Why?
|
| Placebos | 1 | 1971 | 44 | 0.000 |
Why?
|
| Potassium | 1 | 1971 | 25 | 0.000 |
Why?
|
| Sodium | 1 | 1971 | 30 | 0.000 |
Why?
|
| Body Weight | 1 | 1971 | 111 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1971 | 317 | 0.000 |
Why?
|